Navigation Links
Adventrx To Develop ANX-188 For Complications Of Arterial Disease
Date:2/28/2013

al hold"; the risk of suspension or termination of a clinical study, including due to lack of adequate funding or patient safety concerns; the potential for institutional review boards or the FDA or other regulatory agencies to require additional nonclinical or clinical studies prior to initiation of planned phase 2 clinical studies of ANX-188 in any particular indication in which ADVENTRX determines to develop ANX-188, including ALI, which likely would increase the total time and cost of development in the indication; the risk that clinical studies of ANX-188 are not successfully executed and/or do not successfully demonstrate its safety or efficacy; the risk that, even if clinical studies are successful, the FDA determines they are not sufficient to support a new drug application; the risk that even if clinical studies of ANX-188 in one indication are successful, clinical studies in another indication may not be successful; ADVENTRX's reliance on contract research organizations (CROs), contract manufacturing organizations (CMOs), and other third parties to assist in the conduct of important aspects of development of ANX-188, including clinical studies, and regulatory activities for ANX-188 and that such third parties may fail to perform as expected; ADVENTRX's ability to obtain additional funding on a timely basis or on acceptable terms, or at all; the potential for ADVENTRX to delay, reduce or discontinue current and/or planned development activities, including clinical studies, partner ANX-188 at inopportune times or pursue less expensive but higher-risk development paths if it is unable to raise sufficient additional capital as needed; the risk that acceptable partnering opportunities for ANX-188 may not be available in particular jurisdictions or indications and, consequently, ADVENTRX may not be able to pursue development of ANX-188 in certain jurisdictions and indications; the risk that the FDA does not grant marketing approval of ANX-188, on a timely basis,
'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX Reviews Data Supporting Development Of ANX-188 In New Indications
2. ADVENTRX To Present At The Cowen And Company 33rd Annual Health Care Conference On March 4
3. ADVENTRX To Present At The 15th Annual BIO CEO & Investor Conference On February 12
4. ADVENTRX Initiates Pivotal Phase 3 Study of ANX-188
5. ADVENTRX Reports Third Quarter 2012 Financial Results
6. ADVENTRX Announces Details Of The Phase 3 Study Of ANX-188
7. ADVENTRX Announces Appointment Of Ted W. Love M.D. To Board Of Directors
8. ADVENTRX Pharmaceuticals To Present At The Rodman & Renshaw Annual Global Investment Conference On September 10
9. ADVENTRX Announces Appointment Of Chief Medical Officer
10. ADVENTRX Pharmaceuticals to Present at 1st Annual Sickle Cell Disease Therapeutics Conference
11. ADVENTRX Applauds Inclusion of Rare Diseases Provisions in the FDA Safety and Innovation Act
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014  Advanced Medical Isotope Corporation ("AMIC") ... in the development of brachytherapy devices and medical ... that it has filed a de novo ... ("FDA") for marketing clearance for its patented Y-90 ... U.S. Food, Drug and Cosmetic Act (the "Act").  ...
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... decision support to healthcare providers for behavioral health ... has secured $30 million in equity financing from ... C. Drosos , President and Chief Executive Officer. ... adoption and development of Assurex Health,s GeneSight ...
(Date:12/24/2014)... SANTA BARBARA, Calif. , Dec. 23, 2014 ... the Junior Doctors, Association of Sierra Leone ... Sierra Leone for the treatment of local ... While a new dedicated Ebola care center was ... Ebola virus, the facility is not available for local Sierra ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2
(Date:12/25/2014)... When head lice hits a home or ... to get rid of it while keeping it from taking ... now have the solution right in their neighborhood: Lice ... Troopers provides full spectrum head lice screening and treatment services ... Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... chronic illnesses can receive effective, less expensive care from a ... to a team of dedicated health care professionals, a new ... ill and need either hospitalization or a trip to the ... home clinic at the University of Texas in Houston versus ...
(Date:12/25/2014)... -- Overeating is common during the holidays, but there are ... says. "Don,t arrive at a party hungry. It may ... be attending a party, but deprivation leads to hunger, and ... Westchester Hospital in Mount Kisco, N.Y., said in a hospital ... day and even to have a snack before attending a ...
(Date:12/25/2014)... Thompson HealthDay Reporter WEDNESDAY, ... in on a "fountain of youth" drug that can delay ... adults, a new study suggests. Seniors received a significant ... targets a genetic signaling pathway linked to aging and immune ... The experimental medication, a version of the drug rapamycin, ...
(Date:12/25/2014)... December 25, 2014 Thousands of transvaginal ... forward in a number of multidistrict litigations currently underway ... Bernstein Liebhard LLP reports. According to an Order issued ... convene a Joint Status Conference in all of the ... have been directed to submit a proposed agenda to ...
Breaking Medicine News(10 mins):Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4
... proportion of patients with advanced cancer and a life ... common cancer screening tests that are unlikely to provide ... 13 issue of JAMA . Cancer ... (PSA) and colonoscopy, evaluate asymptomatic patients for the detection ...
... Goodwin HealthDay Reporter , TUESDAY, Oct. 12 (HealthDay ... transfusions do just as well as those who receive more, ... varies widely among U.S. hospitals. The studies are published ... the American Medical Association . In the first study, ...
... GABLES, FL (October 12, 2010)--Still hampered by workforce shortages ... care to the full extent of their education and ... the arm they need to transform their profession with ... recommending sweeping changes for improving their profession. The report, ...
... By Kathleen Doheny HealthDay Reporter , TUESDAY, Oct. ... cancer care has long been known by researchers, with ... cancer treatments than white patients. "Less well known is ... something else contributing?" said Dr. Rachel Freedman, a medical ...
... of a large Phase-III clinical trial have shown that ... a hard-to-treat group of rare cancers that affect particular ... European Society for Medical Oncology (ESMO), Dr Marianne Pavel ... improved progression-free survival by 5.1 months in patients with ...
... population ages, health care epidemiologist Padma Kaul and cardiologist Paul ... the University of Alberta, want health-care professionals to talk to ... it be at home, in hospital or a palliative care ... recent study, that the majority of heart failure patients pass ...
Cached Medicine News:Health News:Considerable proportion of patients with advanced cancer continue to undergo common cancer screening 2Health News:Considerable proportion of patients with advanced cancer continue to undergo common cancer screening 3Health News:Heart Surgery Patients Do Fine With Fewer Blood Transfusions: Study 2Health News:Heart Surgery Patients Do Fine With Fewer Blood Transfusions: Study 3Health News:National committee releases findings on transforming and improving the nursing profession 2Health News:Insurance, Income Don't Explain 'Race Gap' in Breast Cancer Care 2Health News:Insurance, Income Don't Explain 'Race Gap' in Breast Cancer Care 3Health News:Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors 2Health News:Medical researchers break down costs to care for heart failure patients at the end of life 2
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
The CE marked HF coagulator which meets the highest ISO safety features....
Finesse electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
Medicine Products: